Curis Alternatives & Competitors
12 companies similar to Curis — Working relentlessly to develop innovative and differentiated therapeutics that...
Companies similar to Curis
Flare Therapeutics
Trailblazing the path to drugging transcription factors to discover precision medicines fo...
Apollomics
We are a biopharmaceutical company committed to the discovery and development of mono- and...
Agennix
Crafting novel therapies to enhance the length and quality of life for seriously ill patie...
Redx Pharma
Biotech company focusing on the discovery and development of novel targeted medicines to t...
Rival Readout
Competing with Curis? We do this properly.
10 rivals, 90 days of dated moves, ranked by what matters and sourced, in 7 business days.
Pacylex Pharmaceuticals, Inc.
A new target in cancer care - triggering selective lethality with a new class of drugs.
Arcus Biosciences
Biopharmaceutical company developing differentiated molecules and combination therapies fo...
Synta Pharmaceuticals
Innovating patient care with advanced small molecule therapies for severe medical conditio...
Inspirna, Inc.
Converting cancer to a manageable, chronic condition
FibroGen, Inc.
Committed to being a place where our people and science thrive.
Tarveda Therapeutics
To discover, develop and commercialize a new class of potent and selective precision oncol...
Scorpion Therapeutics
Pioneering the Next Generation of Precision Oncology
About Curis
Curis, a publicly-traded biotechnology company (NASDAQ: CRIS), focuses on developing first-in-class and innovative therapeutics for cancer treatment. The company has three drug candidates in development: Emavusertib (CA-4948), CI-8993, and Fimepinostat. It also collaborates with Aurigene for immuno-oncology and precisi...
Oncology, Drug Development, Immunology, Clinical Development, Hematology, Therapeutics, Cancer Treatment, Small Molecule Inhibitors, Monoclonal Antibodies, Precision Oncology, Signal Pathway Drug Technologies, Collaborative Research, Publicly-Traded Company, Biomolecular Research
Frequently Asked Questions
From the desk
Mapping a market? Start with a Rival Readout.
In 7 business days we read 10 rivals around Curis: 90 days of dated moves, ranked by what matters to you, each with its source. Fully credited if you continue.
Compiled from the BounceWatch company index. We last looked at Curis on 9 Nov 2024. The 12 companies listed here were last checked between 11 Sep 2024 and 22 Jun 2026. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.